title: Postmenopausal breast cancer: a best endocrine strategy?
authors.affiliation: Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Erica L
authors.initials: EL
authors.lastname: Mayer
authors.affiliation: Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: hburstein@partners.org.
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen